The strong durability and immunogenicity data support EVX-01's clinical promise; traders should position ahead of the H2 2026 three-year data readout, which could serve as a major value driver. Watch for potential partnership or licensing interest ahead of data disclosure.
Price Chart
Executive Summary
Evaxion announced the successful completion of the one-year extension of its phase 2 trial for its personalized cancer vaccine EVX-01, with three-year clinical efficacy data expected in the second half of 2026. The trial has already shown a 75% Objective Response Rate and high durability, with 92% of patients still responding at two years and no relapses observed.
Key Facts
- Phase 2 trial extension completed; final three-year data expected in H2 2026
- Objective Response Rate of 75% (12 of 16 patients) with 4 complete responses
- 92% of patients maintained response at two-year follow-up; no relapses observed
- EVX-01 induced immune response in 100% of patients; 81% of targeted neoantigens generated potent T-cell responses
- Vaccine evaluated in advanced melanoma, combining EVX-01 with Keytruda® followed by monotherapy in year three
Financial Impact
Potential catalyst for value inflection pending 2026 data readout; current market cap of $31M reflects high risk/reward profile
Risk Factors
- Clinical trial results remain early-stage with small sample size (n=16)
- Future data may not maintain current efficacy or durability trends
- High market expectations could lead to sell-off if 2026 data is merely incremental
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3269035 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 6-K | $3.07 $3.21 | ▲ +4.56% | ▲ +4.45% | $3.21 (+4.63%) |
Sep 4, 2026 28d ago | 6-K | $3.12 $3.07 | ▲ +1.60% | ▲ +0.39% | $3.21 (−2.96%) |
Aug 20, 2026 6w ago | 6-K | $3.28 $3.15 | ▼ −3.96% | ▼ −5.08% | $3.21 (−2.07%) |
Aug 20, 2026 6w ago | Press Release | $3.28 $3.15 | ▼ −3.96% | ▼ −5.08% | $3.21 (−2.07%) |
Aug 17, 2026 6w ago | 6-K | $3.13 $3.40 | ▲ +8.63% | ▲ +9.82% | $3.21 (+2.63%) |
Aug 14, 2026 7w ago | 6-K | $3.34 $3.31 | ▼ −0.90% | ▲ +0.47% | $3.21 (−3.83%) |
Aug 14, 2026 7w ago | Press Release | $3.34 $3.31 | ▼ −0.90% | ▲ +0.47% | $3.21 (−3.83%) |
Jul 17, 2026 11w ago | 6-K | $3.08 $3.05 | ▼ −0.81% | ▼ −0.13% | $3.21 (+4.46%) |
Jul 17, 2026 11w ago | Press Release | $3.08 $3.05 | ▼ −0.81% | ▼ −0.13% | $3.21 (+4.46%) |
Jul 13, 2026 11w ago | 6-K | $3.02 $3.08 | ▲ +1.82% | ▲ +2.61% | $3.21 (+6.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access